Medeon Biodesign, Inc.

Medeon Biodesign, Inc.

TTPEX:6499
67.30
TWD
-1.60
(-2.32%)
-6.50EPS
6.83BMarket Cap
Mar 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.41
2.08
8.42
4.95
1.33
0.75
3.21
2.13
3.18
4.54
4.7
Basic EPS, GAAP
-1.83
-1.2
-2.25
-3.04
-3.12
3.21
-2.86
-2.08
22.65
-4.67
-13.09
-8.74
-7.24
-5.92
Free Cash Flow per Basic Share
-2.73
-1.37
-2.38
-2.77
-5.8
3.35
-3.2
-1.86
-3.3
-6.48
-8.81
-9.85
-7
-5.41
Dividend per Share
- -
- -
- -
- -
- -
0.01
0.01
0.33
- -
0.79
0.48
- -
- -
- -
Book Value per Share
6.25
5.12
12.88
20.32
16.93
20.62
21.75
22.32
44.89
39.1
25.21
16.5
15.22
12.69
Tangible Book Value per Share
6.01
4.91
12.68
17.09
13.38
17.28
19.13
19.99
44.03
37.14
23.35
14.74
13.65
11.17
Basic Weighted Avg Shares
18
60
66
72
79
80
92
93
92
93
92
92
92
95
Sales/Revenue/Turnover
- -
- -
- -
29
165
674
454
123
69
298
196
293
419
446
Operating Margin (%)
- -
- -
- -
-774.21
-166
25.92
-56.57
-278.04
-718.69
-163.53
-427.48
-297.87
-172.25
-137.73
Depreciation Expense
2
4
5
10
39
51
79
84
59
64
96
99
107
104
Net Income, GAAP
-33
-73
-148
-219
-248
257
-262
-193
2,078
-434
-1,205
-806
-668
-562
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-746.39
-150.22
38.1
-57.74
-156.62
3,013.75
-145.4
-613.78
-275.1
-159.28
-125.94
Working Capital
380
308
851
1,394
1,055
1,337
1,777
2,222
2,230
1,439
2,006
1,102
1,161
914
LT Debt
- -
- -
- -
- -
- -
- -
97
469
16
162
140
114
72
109
Total Equity
401
332
875
1,676
1,533
1,798
2,249
2,648
4,188
3,664
2,371
1,536
1,537
1,269
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-15.76
-20.46
-24.93
-17.76
-16.86
17.21
-14.38
-9.52
67.31
-11.23
-40.71
-41.95
-44.6
-43.67

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
41
46
43
LT Borrowings
- -
- -
- -
LT Finance Leases
72
117
109
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
9,161
8,696
6,835

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,322
1,182
1,079
Cash, Cash Equivalents & STI
1,220
1,067
960
Accounts Receivable, Net
39
46
43
Inventories
25
28
30
Total Current Liabilities
161
144
164
Payables & Accruals
- -
- -
- -
ST Debt
41
46
43
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.84%
-4.95%
0.06%
Free Cash Flow
-5.93%
38.45%
-28.81%
Net Income, GAAP
-154.3%
-234.32%
-17.06%
Sales/Revenue/Turnover
- -
69.37%
43.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
64
105
77
293
2025
102
110
- -
115
419
2026
114
107
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2.17
-2.31
-2
-2.24
-8.74
2025
-1.91
-1.93
- -
-1.48
-7.24
2026
-1.26
-1.28
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Yu Te Chang
Full Time Employees
1,496
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
116, HouGang Street Taipei TP Taiwan 11170
IPO Date
Jul 27, 2016
Business
Medeon Biodesign, Inc. (6499.TWO) researches, develops, manufactures, and sells medical devices focused on minimally invasive surgeries and treatments; its core products include Cross-Seal, a large bore vascular closure system; Urocross, an expander system and retrieval sheath for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, a solution for orthopedic extremity injuries; ClickClean, a laparoscope lens shield device; AbClose, a trocar wound closure device to prevent port site herniation; and XFLO, a minimally invasive BPH treatment device. The company also provides contract development and manufacturing organization (CDMO) services through its subsidiary Medeologix Corporation, encompassing medical tubing extrusion, balloon forming, catheter processing, final assembly, packaging, and logistics; it further offers injection molding and components for medical devices. Founded in 2012 and headquartered at 7F, 116 HouGang Street, Taipei 11170, Taiwan, Medeon Biodesign operates primarily in the healthcare equipment sector, serving physicians, medtech entrepreneurs, and global medical companies with a presence in Taiwan, the United States (Sunnyvale, California), and international markets. Recent developments include U.S. FDA 510(k) clearance for the PUMA System and AbClose Trocar Wound Closure Device; FDA Investigational Device Exemption approval and first-in-human clinical trial clearance for Duett; positive interim clinical results for XFLO; FDA PMA approval for Cross-Seal with completed cGMP inspection; establishment of Medeologix with acquisitions of MediBalloon and Second Source Medical to expand CDMO capabilities; investments in Prodeon for the Mercury Project (URO-T01) and Delta Asia International Co. (now publicly listed as 6762.TWO); successful secondary public offering; and recent 2025 announcements of Urocross Expander System submission for FDA 510(k) clearance, Urocross Retrieval Sheath FDA 510(k) clearance, and cash capital increases.